NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $23.98 +1.69 (+7.58%) Closing price 04:00 PM EasternExtended Trading$23.86 -0.12 (-0.50%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 10x Genomics Stock (NASDAQ:TXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 10x Genomics alerts:Sign Up Key Stats Today's Range$21.99▼$24.0550-Day Range$16.69▼$26.0852-Week Range$8.06▼$26.44Volume2.93 million shsAverage Volume2.62 million shsMarket Capitalization$3.04 billionP/E RatioN/ADividend YieldN/APrice Target$23.17Consensus RatingHold Company Overview 10x Genomics, Inc. is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations. The company has established regional operations and support centers across North America, Europe and Asia to facilitate training, technical support and collaborations with leading research laboratories. 10x Genomics has built its reputation on enabling new discoveries in fields such as oncology, immunology, neuroscience and developmental biology. By combining microfluidics, novel chemistry and bioinformatics software, the company’s solutions aim to simplify workflow complexity and accelerate data generation and interpretation for large-scale studies. Co-founded by Serge Saxonov, Ben Hindson and Kevin Ness, 10x Genomics continues to expand its product portfolio through ongoing research and development. The company’s integrated approach to single-cell and spatial biology is designed to empower scientists worldwide to uncover cellular heterogeneity, identify therapeutic targets and drive innovation in precision medicine.AI Generated. May Contain Errors. Read More 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreTXG MarketRank™: 10x Genomics scored higher than 32% of companies evaluated by MarketBeat, and ranked 748th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 4 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for 10x Genomics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst Coverage10x Genomics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($0.82) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -141.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -141.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 3.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.95% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 6.12.Change versus previous monthShort interest in 10x Genomics has recently decreased by 1.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.28 News Sentiment10x Genomics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for 10x Genomics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $902,695.00 in company stock.Percentage Held by Insiders8.84% of the stock of 10x Genomics is held by insiders.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXG Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Solventum Corporation (SOLV)May 15, 2026 | theglobeandmail.com10x Genomics (NASDAQ:TXG) Receives Consensus Rating of "Hold" from AnalystsMay 15, 2026 | americanbankingnews.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)May 14, 2026 | theglobeandmail.comThe 5 most interesting analyst questions from 10x Genomics’s Q1 earnings callMay 14, 2026 | msn.comIs It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?May 14, 2026 | finance.yahoo.com10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comJPMorgan Chase & Co. Issues Positive Forecast for 10x Genomics (NASDAQ:TXG) Stock PriceMay 13, 2026 | americanbankingnews.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $16.31 at the start of the year. Since then, TXG stock has increased by 47.0% and is now trading at $23.98. How were 10x Genomics' earnings last quarter? 10x Genomics (NASDAQ:TXG) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.19. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $370 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 10,000,000 shares at $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? Top institutional investors of 10x Genomics include Quantinno Capital Management LP (4.26%), Sumitomo Mitsui Trust Group Inc. (4.00%), Amova Asset Management Americas Inc. (4.00%) and Dimensional Fund Advisors LP (1.60%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Justin J Mcanear, James Wilbur and Alan Mateo. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today5/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TXG's financial health is in the Green zone, according to TradeSmith. TXG has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,240Year Founded2012Price Target and Rating Average Price Target for 10x Genomics$23.17 High Price Target$32.00 Low Price Target$17.00 Potential Upside/Downside-3.4%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.54 million Net Margins-3.55% Pretax Margin-3.01% Return on Equity-2.86% Return on Assets-2.23% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.42 Sales & Book Value Annual Sales$642.82 million Price / Sales4.74 Cash FlowN/A Price / Cash FlowN/A Book Value$6.41 per share Price / Book3.74Miscellaneous Outstanding Shares126,960,000Free Float115,733,000Market Cap$3.04 billion OptionableOptionable Beta2.05 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:TXG) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
